# EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.

Study · id `cardio:ct-nct04743453` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04743453](<https://clinicaltrials.gov/study/NCT04743453>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04743453

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 211 participants.

## Technical summary

Registry record NCT04743453. Randomized; double masking; primary purpose treatment. Start 2021-08-17 (actual); primary completion 2024-09-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 211 participants (enrolled count; ClinicalTrials.gov record NCT04743453, source copy `cardio:ctgov-nct04743453-2024-09-05`, retrieved 2026-10-26)
- Started: 2021-08-17 (actual) (ClinicalTrials.gov record NCT04743453, source copy `cardio:ctgov-nct04743453-2024-09-05`, retrieved 2026-10-26)
- Primary completion: 2024-09-02 (actual) (ClinicalTrials.gov record NCT04743453, source copy `cardio:ctgov-nct04743453-2024-09-05`, retrieved 2026-10-26)
- Completion: 2024-09-02 (actual) (ClinicalTrials.gov record NCT04743453, source copy `cardio:ctgov-nct04743453-2024-09-05`, retrieved 2026-10-26)
- Countries: Brazil (ClinicalTrials.gov record NCT04743453, source copy `cardio:ctgov-nct04743453-2024-09-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04743453-2024-09-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.
- Condition: Kidney Transplantation
- Condition: Diabetes Mellitus, Type 2
- Condition: Diabetes Complications
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: University of Sao Paulo General Hospital
- Lead sponsor class: OTHER
- Collaborator: Federal University of São Paulo
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: University of Sao Paulo General Hospital (`cardio:org-university-of-sao-paulo-general-hospital`)
- Registry lists this organization as a collaborator: Federal University of São Paulo (`cardio:org-federal-university-of-sao-paulo`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The Effect of Adding Dapagliflozin on Chronic Renal Allograft Dysfunction: A Randomized, Prospective, Double-blind, Placebo-controlled Trial (`cardio:pubmed-42102257`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: acc841909639916f14a2164f94f39dcf9f6dbcbe6116a2e44a622126d0d60529
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
